Pharmacokinetics of acebutolol enantiomers after intravenous administration of racemate in a rat model: A dosing range comparison

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 5, 1997, Pages 397-408

  Mostafavi, S Abolfazl ^a   Foster, Robert T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acebutolol; Enantiomer; Linearity; Pharmacokinetics; Rat

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIACETOLOL;

AREA UNDER THE CURVE; ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LINEAR SYSTEM; MALE; NONHUMAN; RACEMIC MIXTURE; RAT;

ACEBUTOLOL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 0030877665     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199707)18:5<397::AID-BDD27>3.0.CO;2-R     Document Type: Article

References (37)

1. D. G. McDevitt, Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur. Heart J., 8 (suppl. M), 9-14 (1987).
2. A. H. Gradman, R. A. Winkle, J. W. Fitsgerald, P. J. Meffin, J. Stoner, P. A. Bell and D. C. Harrison, Suppresion of premature ventricular contractions by acebutolol. Circulation, 55, 785-791 (1977).
3. P. Biron and G. Tremblay, Differential antianginal responsiveness to acebutolol. Eur. J. Clin. Pharmacol., 8, 15-19 (1975).
4. T. Walle, J. G. Webb, E. E. Bagwell, U. K. Walle, H. B. Daniell and T. E. Gaffiney, Stereoselective delivery and actions of beta receptor antagonists. Biochem. Pharmacol., 37, 115-124 (1998).
5. R. A. Winkle, P. J. Meffin, W. B. Ricks and D. C. Harrison, Acebutolol metabolite plasma concentration during chronic oral therapy. Br. J. Clin. Pharmacol., 4, 519-522 (1977).
6. M. Piquette-Miller, R. T. Foster, C. T. Kappagoda and F. Jamali, Pharmacokinetics of acebutolol enantiomers in humans. J. Pharm. Sci., 80, 313-316 (1991).
7. M. Piquette-Miller and F. Jamali, Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agent Actions, 37, 290-296 (1992).
8. C. M. Kaye and A. D. Long, The influence of PH on the buccal absorption and plasma and renal elimination of acebutolol. Br. J. Clin. Pharmacol., 3, 196-198 (1976).
9. P. J. Meffin, S. R. Harapat and D. C. Harrison, Quantitation in plasma and urine of acebutolol and major metabolite with preliminary observations on their disposition kinetics in man. Res. Commun. Chem. Pathol. Pharmacol., 15, 31-51 (1976).
10. P. J. Meffin, R. A. Winkle, F. A. Peters and D. C. Harrison, Acebutolol disposition after intravenous administration. Clin. Pharmacol. Ther., 22, 557-567 (1977).
11. P. J. Meffin, R. A. Winkle, F. A. Peters and D. C. Harrison, Dose-dependent acebutolol disposition after oral administration. Clin. Pharmacol. Ther., 24, 542-547 (1978).
12. M. G. Sankey, A. Gulaid and C. M. Kaye, Preliminary study of the disposition in man of acebutolol and its metabolite, diacetolol using a new stereoselective HPLC method. J. Pharm. Pharmacol., 36, 276-277 (1984).
13. D. G. De Bono, C. M. Kaye, E. Roland and A. J. Summers, Acebutolol: ten years of experience. Am. Heart J., 109, 1211-1223 (1985).
14. B. N. Singh, W. R. Thoden and J. Wahl, Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy, 6, 45-63 (1986).
15. T. J. Coombs, C. J. Coulson and V. J. Smith, Blood plasma binding of acebutolol and diacetolol in man. Br. J. Clin. Pharmacol., 9, 395-397 (1980).
16. M. Piquette-Miller, R. T. Foster, F. M. Pasutto and F. Jamali, Stereoselective high-performance liquid chromatographic assay of acebutolol in human plasma and urine. J. Chromatogr., 529, 129-137 (1990).
17. M. Piquette-Miller and R. T. Foster, High-performance liquid chromatographic determination of diacetolol. J. Chromatogr., 533, 303-303 (1990).
18. A. Roux, J. Guedon and B. Flouvat, Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur. J. Clin. Pharmacol., 17, 339-348 (1980).
19. M. Piquette-Miller, R. T. Foster, C. T. Kappagoda and F. Jamali, Effect of aging on the pharmacokinetics of acebutolol enantiomers. J. Clin. Pharmacol., 32, 148-156 (1992).
20. O. Okazaki, T. Kurata, H. Hakusui and H. Tachizawa, Species related stereoselective disposition of ofloxacin in the rat, dog and monkey. Xenobiotica, 22, 439-450 (1992).
21. Statistical Consultants, Inc. PCNONLIN User Guide, Version 4.0, SCI Software, Lexington, KT 1992.
22. B. Basil, R. F. Collins and M. F. Cuthbert, Pharmacokinetics of m & b 17,803a in animals and man. Br. J. Pharmacol., 47, 620p (1973).
23. W. Kirch, H. Kohler, G. Berggren and W. Braun, The influence of renal function on plasma levels and urinary excretion of acebutolol and its main n-acetyl metabolite. Clin. Nephrol., 18, 88-94 (1982).
24. R. Zaman, M. R. Wilkins, M. J. Kendall and D. B. Jack, The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite diacetolol. Biopharm. Drug Disposit., 5, 91-95 (1984).
25. R. Zaman, D. B. Jack, M. R. Wilkins and M. J. Kendall, Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study. Biopharm. Drug Disposit., 6, 131-137.
26. M. Piquetee-Miller and F. Jamali, Multiple peaking of acebutolol enantiomers in the rat. Pharm. Res., 9 (suppl.), S-161 (1992).
27. M. L. Thomas, Nonlinear pharmacokinetics (clinical implications). Clin. Pharmacokinet., 20, 429-446 (1991).
28. B. M. Silber, N. H. Holford and S. Riegelman, Dose-dependent elimination of propranolol and its major metabolites in humans. J. Pharm. Sci., 72, 725-732 (1983).
29. F. Jamali, R. Mehvar and F. M. Pasutto, Enantioselective aspect of drug and disposition: therapeutic pitfalls. J. Pharm. Sci., 78, 695-715 (1989).
30. T. Walle, Stereochemistry of the invivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates. Drug Metab. Disposit., 13, 279-282 (1985).
31. Davies B. and T. Morris, Physiological parameters in laboratory animals and humans. Pharm. Res., 10, 1093-1095 (1993).
32. R. A. Boyd, S. K. Chin, O. Don-Pedro, R. L. Williams and K. M. Giacomini, The pharmacokinetics of the enantiomers of atenolol. Clin. Pharmacol. Ther., 45, 403-410 (1989).
33. R. Mehvar, M. E. Gross and R. N. Kreamer, Pharmacokinetics of atenolol enantiomers in humans and rats. J. Pharm. Sci., 79, 881-885 (1990).
34. R. Gabriel, C. M. Kaye and M. G. Sankey, Preliminary observations on the excretion of acebutolol and its acetyl metabolites in the urine and feces of man. J. Pharm. Pharmacol., 33, 386-387 (1981).
35. A. Roux, B. Flouvat, Y. Fouache and J. P. Bourdarias, Systemic bioavailability of acebutolol in man. Biopharm. Drug Disposit., 4, 293-297 (1983).
36. J. H. Lin, E. H. Ulm and E. L. Layne, Dose-dependent stereopharmacokinetics of 5,6-dihydro-4H-4(isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7,7-dioxide, a potent carbonic anhydrase inhibitor, in rats. Drug Metab. Disposit., 19, 233-238 (1991).
37. B. Flouvat, A. Roux, N. P. Chau, M. Viallet, X. Andre-Fouet, R. Woehrle and J. Gregoire, Pharmacokinetics and bioavailability of diacetolol, the main metabolites of acebutolol. Eur. J. Clin. Pharmacol., 19, 287-292 (1981).